FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2909528087> ?p ?o ?g. }

• W2909528087 endingPage "1865" @default.
• W2909528087 startingPage "1865" @default.
• W2909528087 abstract "Abstract Introduction: Unprecedented clinical outcomes were reported after CD19 chimeric antigen receptor T cell (CART19) therapy and led to their FDA approval in diffuse large B cell lymphoma and in acute lymphoblastic leukemia. However, the complete response rate in chronic lymphocytic leukemia (CLL) after CART19 therapy is much lower, at approximately 20-30%, and the mechanism(s) for this relative lack of success is unclear. The dominant known mechanism(s) that prevent successful CART cell therapy in CLL have been limited to CART expansion and poor persistence. However, potential mechanisms are not limited to the CLL T-cell. Several immune defects have been identified in CLL that result from the complex bi-directional interaction between B-CLL cells and their microenvironment. In CLL the leukemic microenvironment is rich with extracellular vesicles (EVs) secreted by B-CLL cells. There is growing evidence that these vesicles play an important role in intracellular communication by the delivery of growth factors, genetic material and microenvironmentally relevant molecules. Therefore, we aimed to investigate the role and interactions of EVs in the diminished or absent CART response seen in some CLL patients. Methods: EVs were isolated from peripheral blood of 16 patients with untreated CLL at different Rai stages (8 patients had early and 8 had advanced stage disease) and risk profile by FISH (8 patients had low risk and 8 patients had high risk disease, based on the presence of 17p deletion). Cytometry was used to determine size, number of particles per µl, Annexin V and CD19 expression. These variables were correlated to the Rai stage and risk category of the disease. To investigate the impact of EVs on CART cell functions, CART19 cells were stimulated with either CLL EVs alone or in combination with the CD19 positive cell line JeKo1. After coincubation different effector functions were analysed. Results: Two patterns of EVs in CLL patients were identified; a single versus two distinct EV size populations (small [EVssmall]; 50-240nm, median=110nm) and large [EVslarge]; 180-560nm, median = 360nm Fig 1.A). In 25% of patients, EVs were CD19 positive (EVCD19+). CD19 positivity was detected only in patients with the EVslarge (Fig 1.B). The EVs concentration, CD19 expression (EVsCD19+ vs EVsCD19-), or the size (EVssmall vs EVslarge) did not correlate with disease stage (early vs advanced Rai stage) or risk profile of CLL (low vs high risk) although some variation could be seen (Fig 1.C). To investigate our hypothesis that EVs could modulate CART19 function, CART19 cell effector functions were examined in the presence of EVsCD19+, EVsCD19-, EVssmall, or EVslarge. EVs, 1.5x10e5 particles, alone were insufficient to stimulate CART19 cells. However when CART19 cells were stimulated with the CD19 positive cell line JeKo1, their effector functions were reduced only in the presence of EVsCD19+, 50,000 particles, 2.5 x 10e3/ µl, but not EVsCD19- at the same concentration. This included a significant reduction in CART specific killing (Fig 1.D) and a reduction in cytokine production. The impairment of CART cell functions was independent of the size of EVs, i.e. there was no impairment of CART functions with large or small size EVCD19- in co-culture. Summary: We identify CD19 positive large size EVs from patients with CLL and demonstrate that these EVs play a role in the leukemic microenvironment by reducing CART cell activity. Studies are ongoing to define the mechanism(s). Disclosures Parikh: Janssen: Research Funding; AstraZeneca: Honoraria, Research Funding; Pharmacyclics: Honoraria, Research Funding; Gilead: Honoraria; MorphoSys: Research Funding; Abbvie: Honoraria, Research Funding. Kay:Cytomx Therapeutics: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Acerta: Research Funding; Infinity Pharm: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Agios Pharm: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Morpho-sys: Membership on an entity's Board of Directors or advisory committees; Tolero Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees. Kenderian:Tolero Pharmaceuticals: Research Funding; Humanigen: Research Funding; Novartis: Patents & Royalties." @default.
• W2909528087 created "2019-01-25" @default.
• W2909528087 creator A5000383195 @default.
• W2909528087 creator A5002515721 @default.
• W2909528087 creator A5009747339 @default.
• W2909528087 creator A5022820232 @default.
• W2909528087 creator A5041136366 @default.
• W2909528087 creator A5049052893 @default.
• W2909528087 creator A5054196868 @default.
• W2909528087 creator A5060229988 @default.
• W2909528087 creator A5066931453 @default.
• W2909528087 creator A5067492340 @default.
• W2909528087 creator A5072545362 @default.
• W2909528087 creator A5086525280 @default.
• W2909528087 creator A5088390990 @default.
• W2909528087 creator A5090781979 @default.
• W2909528087 date "2018-11-29" @default.
• W2909528087 modified "2023-10-14" @default.
• W2909528087 title "Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions" @default.
• W2909528087 doi "https://doi.org/10.1182/blood-2018-99-119484" @default.
• W2909528087 hasPublicationYear "2018" @default.
• W2909528087 type Work @default.
• W2909528087 sameAs 2909528087 @default.
• W2909528087 citedByCount "0" @default.
• W2909528087 crossrefType "journal-article" @default.
• W2909528087 hasAuthorship W2909528087A5000383195 @default.
• W2909528087 hasAuthorship W2909528087A5002515721 @default.
• W2909528087 hasAuthorship W2909528087A5009747339 @default.
• W2909528087 hasAuthorship W2909528087A5022820232 @default.
• W2909528087 hasAuthorship W2909528087A5041136366 @default.
• W2909528087 hasAuthorship W2909528087A5049052893 @default.
• W2909528087 hasAuthorship W2909528087A5054196868 @default.
• W2909528087 hasAuthorship W2909528087A5060229988 @default.
• W2909528087 hasAuthorship W2909528087A5066931453 @default.
• W2909528087 hasAuthorship W2909528087A5067492340 @default.
• W2909528087 hasAuthorship W2909528087A5072545362 @default.
• W2909528087 hasAuthorship W2909528087A5086525280 @default.
• W2909528087 hasAuthorship W2909528087A5088390990 @default.
• W2909528087 hasAuthorship W2909528087A5090781979 @default.
• W2909528087 hasBestOaLocation W29095280871 @default.
• W2909528087 hasConcept C203014093 @default.
• W2909528087 hasConcept C2776090121 @default.
• W2909528087 hasConcept C2777938653 @default.
• W2909528087 hasConcept C2778461978 @default.
• W2909528087 hasConcept C2778957590 @default.
• W2909528087 hasConcept C3875195 @default.
• W2909528087 hasConcept C502942594 @default.
• W2909528087 hasConcept C71924100 @default.
• W2909528087 hasConcept C86803240 @default.
• W2909528087 hasConcept C8891405 @default.
• W2909528087 hasConceptScore W2909528087C203014093 @default.
• W2909528087 hasConceptScore W2909528087C2776090121 @default.
• W2909528087 hasConceptScore W2909528087C2777938653 @default.
• W2909528087 hasConceptScore W2909528087C2778461978 @default.
• W2909528087 hasConceptScore W2909528087C2778957590 @default.
• W2909528087 hasConceptScore W2909528087C3875195 @default.
• W2909528087 hasConceptScore W2909528087C502942594 @default.
• W2909528087 hasConceptScore W2909528087C71924100 @default.
• W2909528087 hasConceptScore W2909528087C86803240 @default.
• W2909528087 hasConceptScore W2909528087C8891405 @default.
• W2909528087 hasIssue "Supplement 1" @default.
• W2909528087 hasLocation W29095280871 @default.
• W2909528087 hasOpenAccess W2909528087 @default.
• W2909528087 hasPrimaryLocation W29095280871 @default.
• W2909528087 hasRelatedWork W2155044513 @default.
• W2909528087 hasRelatedWork W2412656109 @default.
• W2909528087 hasRelatedWork W2801641802 @default.
• W2909528087 hasRelatedWork W2952849902 @default.
• W2909528087 hasRelatedWork W3129071892 @default.
• W2909528087 hasRelatedWork W3158561770 @default.
• W2909528087 hasRelatedWork W40408739 @default.
• W2909528087 hasRelatedWork W4221094972 @default.
• W2909528087 hasRelatedWork W4280509433 @default.
• W2909528087 hasRelatedWork W4361920761 @default.
• W2909528087 hasVolume "132" @default.
• W2909528087 isParatext "false" @default.
• W2909528087 isRetracted "false" @default.
• W2909528087 magId "2909528087" @default.
• W2909528087 workType "article" @default.